Could inhibition of the proteasome cause mad cow disease?

Trends in Biotechnology

Volumn 21, Issue 4, 2003, Pages 144-145

  Hooper, Nigel M ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CONTROL; PROTEINS;

NEUROTOXIC PROPERTIES;

BIOTECHNOLOGY;

PRION PROTEIN; PROTEASOME; PROTEASOME INHIBITOR;

BIOTECHNOLOGY;

BOVINE SPONGIFORM ENCEPHALOPATHY; BRAIN SPONGIOSIS; CHROMOSOME TRANSLOCATION; DRUG SCREENING; ENZYME DEGRADATION; EVALUATION; HUMAN; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEINASE INHIBITION; SHORT SURVEY;

BOVINAE;

EID: 0037383010     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(03)00026-X     Document Type: Short Survey

References (17)

1. Cushman D.W., Ondetti M.A. Design of angiotensin converting enzyme inhibitors. Nature Med. 5:1999;1110-1112.
2. Tomasselli A.G., Heinrikson R.L. Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochim. Biophys. Acta. 1477:2000;189-214.
3. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:2002;353-356.
4. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol. Med. 8:2002;S49-S54.
5. Doherty F., et al. The ubiquitin-proteasome pathway of intracellular proteolysis. Hooper N.M., et al. Essays in Biochemistry: Proteases in Biology and Medicine. vol. 38:2002;51-63 Portland Press, London.
6. Plemper R.K., Wolf D.H. Retrograde protein translocation: ERADication of secretory proteins in health and disease. Trends Biochem. Sci. 24:1999;266-270.
7. Westaway D., Carlson G.A. Mammalian prion proteins: enigma, variation and vaccination. Trends Biochem. Sci. 27:2002;301-307.
8. Prusiner S.B. Prions. Proc. Natl. Acad. Sci. U. S. A. 95:1998;13363-13383.
9. Sc -like conformation in living cells. Nature Cell Biol. 1:1999;358-361.
10. Yedidia Y., et al. Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein. EMBO J. 20:2001;5383-5391.
11. Ma J., Lindquist S. Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc. Natl. Acad. Sci. U. S. A. 98:2001;14955-14960.
12. Ma J., et al. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science. 298:2002;1781-1785.
13. Ma J., Lindquist S. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science. 298:2002;1785-1788.
14. Andre P., et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl. Acad. Sci. U. S. A. 95:1998;13120-13124.
15. Lam Y.A., et al. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 97:2000;9902-9906.
16. Ding Q., Keller J.N. Proteasomes and proteasome inhibition in the central nervous system. Free Radic. Biol. Med. 31:2001;574-584.
17. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron. 29:2001;15-32.